Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Idasanutlin and venetoclax in elderly R/R AML

Naval Daver • 10 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Idasanutlin Venetoclax

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents the updated results of the phase Ib study of the MDM2 inhibitor idasanutlin in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia (AML) who are ineligible for cytotoxic chemotherapy (NCT02670044). The rationale for this is that idasanutlin may help improve the response to venetoclax by promoting the degradation of MCL1 and enhancing the pro-apoptotic pathway. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Naval Daver

New treatments in AML: FLT3 inhibitors & novel combinations
Gail Roboz et al. • 4 Sep 2023
3:53
Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML
Naval Daver • 12 Dec 2022
1:13
The importance of CD47 as a target in MDS and AML
Naval Daver • 12 Dec 2022
3:50
Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AML
Naval Daver • 12 Dec 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals